Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 157.7M shares rose 3.7% year over year, behind the +5.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.7% toward the trailing-twelve-month pace of +5.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
157.7M+1.4% QoQ
Last fiscal yearDec 2025
151.72M+3.1% YoY
LTMJun 2026
157.38M+5.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.7%——
1 year+3.1%——
3-year CAGR+2.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
151.72M USD
Year-over-year change
+3.1%
4-year CAGR
+2.0%

Weighted Avg Shares (Diluted) vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 weighted avg shares (diluted) of 157.38M shares is the 2nd highest of the 10 companies compared; the peer median is 103.77M shares.
  • Its year-over-year change of +5.6% is the 7th highest of 10, against a peer median of +13.4%.
  • Over three fiscal years its annual growth of +2.1% compares with a peer median of +24.4%.
ADPT Competitors Peer median
Weighted Avg Shares (Diluted) for ADPT and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026189.27M +2.9%+5.0%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026157.38M +5.6%+2.1%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026127.2M +1.1%+4.5%
SRRKScholar Rock Holding CorporationLTM Sep 2026126.24M +15.3%+24.4%
ZLABZai Lab LimitedLTM Jun 2026110.81M +34.8%+125.3%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.77M +17.0%+12.2%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.86M +4.6%+28.8%
MLYSMineralys Therapeutics, Inc.LTM Jun 202679.68M +45.9%+135.7%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 202643.89M +7.8%+19.3%
IRONDisc Medicine, Inc.LTM Sep 202637.84M +13.4%+223.8%
Peer median (excluding ADPT) 103.77M+13.4%+24.4%

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue154.34M185.31M170.28M178.96M276.98M
Cost of Revenue49.3M57.91M75.55M72.08M71.36M
Gross Profit105.04M127.4M94.72M106.88M205.62M
Gross Margin68.1%68.7%55.6%59.7%74.2%
Research & Development142.34M141.76M122.12M102.95M93.77M
Selling, General & Admin169.97M184.13M172.51M157.57M167.27M
Operating Expenses314.01M327.59M321.76M269.43M262.74M
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
EBITDA(193.35M)(175.21M)(189.27M)(128.76M)(29.85M)
EBITDA Margin-125.3%-94.6%-111.2%-71.9%-10.8%
Operating Income(208.97M)(200.19M)(227.04M)(162.55M)(57.12M)
Operating Margin-135.4%-108.0%-133.3%-90.8%-20.6%
Interest Income1.67M4.06M15.53M14.53M9.44M
Interest Expense04.24M13.8M11.58M11.78M
Other Income / Expenses1.67M(182K)1.73M2.95M(2.33M)
Income Before Tax(207.3M)(200.37M)(225.3M)(159.6M)(59.46M)
Pre-Tax Margin-134.3%-108.1%-132.3%-89.2%-21.5%
Income Tax Expense00000
Net Income(207.28M)(200.19M)(225.25M)(159.49M)(59.5M)
Net Margin-134.3%-108.0%-132.3%-89.1%-21.5%
EPS (Basic)(1.46)(1.00)(1.56)(1.08)(0.39)
EPS (Diluted)(1.46)(1.00)(1.56)(1.08)(0.39)
Weighted Avg Shares140.35M142.52M144.38M147.1M151.72M
Weighted Avg Shares (Diluted)140.35M142.52M144.38M147.1M151.72M

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.